Cargando…

Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy—effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker

BACKGROUND: Host factors such as angiotensin-converting enzyme 2 (ACE2) and the transmembrane protease, serine-subtype-2 (TMPRSS2) are important factors for SARS-CoV-2 infection. Clinical and pre-clinical studies demonstrated that RAAS-blocking agents can be safely used during a SARS-CoV-2 infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Yingquan, Delic, Denis, Zeng, Shufei, Chen, Xin, Chu, Chang, Hasan, Ahmed A., Krämer, Bernhard K., Klein, Thomas, Yin, Lianghong, Hocher, Berthold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942812/ https://www.ncbi.nlm.nih.gov/pubmed/35331159 http://dx.doi.org/10.1186/s12882-022-02747-1

Ejemplares similares

C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival
por: Chu, Chang, et al.
Publicado: (2021)

Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
por: Chu, Chang, et al.
Publicado: (2020)

DPP4 inhibition prevents AKI
por: Reichetzeder, Christoph, et al.
Publicado: (2017)

Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy
por: Delić, Denis, et al.
Publicado: (2020)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

25(OH)D-but not 1,25(OH)(2)D–Is an independent risk factor predicting graft loss in stable kidney transplant recipients
por: Zeng, Shufei, et al.
Publicado: (2023)

Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone
por: Alter, Markus, et al.
Publicado: (2011)

Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
por: Chen, Xin, et al.
Publicado: (2023)

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
por: Chaykovska, Lyubov, et al.
Publicado: (2011)

Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients
por: Zeng, Shufei, et al.
Publicado: (2020)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

Angiotensin receptor blockers (ARBs) in hypertension patients: earlier use of these bettertolerated medications is warranted
por: Aalbers, J
Publicado: (2010)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Biological Activity of Different Forms of Oxidized Parathyroid Hormone
por: Hasan, Ahmed A., et al.
Publicado: (2022)

On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone
por: Konoshita, Tadashi, et al.
Publicado: (2016)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
por: Cha, Seon-Ah, et al.
Publicado: (2017)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Management of Bevacizumab-Induced Proteinuria Using an Angiotensin Receptor Blocker (ARB) in a Neurofibromatosis Type 2 (NF-2) Patient With Vestibular Schwannoma
por: Omene, Egiroh E, et al.
Publicado: (2023)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

N-terminal prohormone B-type natriuretic peptide variability acts as a predictor of poor prognosis in patients with cardiorenal syndrome type 2
por: Ma, Mingming, et al.
Publicado: (2021)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
por: Pires de Souza, Gabriel Augusto, et al.
Publicado: (2021)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
por: Hocher, Berthold, et al.
Publicado: (2022)

Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis
por: Chu, Chang, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Bioinformatic identification of key genes and analysis of prognostic values in clear cell renal cell carcinoma
por: Luo, Ting, et al.
Publicado: (2018)

Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation
por: Costa Gil, José Esteban, et al.
Publicado: (2022)

Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients
por: Zuo, Jiao, et al.
Publicado: (2023)

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
por: Chadha, Manoj, et al.
Publicado: (2022)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series
por: Škrtić, Marko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m4flepv1av7ac4g89oob4heu02